Prospective observational study demonstrates superior prediction of moderate-to-severe exacerbations using CIRS in COPD patients, indicating the value of comprehensive comorbidity assessment.
BACKGROUND AND OBJECTIVE: Chronic Obstructive Pulmonary Disease (COPD) is frequently associated with multiple comorbidities that influence clinical outcomes. This study aimed to compare the predictive performance of the Cumulative Illness Rating Scale (CIRS) with the Charlson Comorbidity Index (CCI) and COMCOLD Index for moderate-to-severe COPD exacerbations. MATERIALS AND METHODS: We conducted a prospective observational study involving 200 COPD patients followed for 52 weeks. CIRS indices (Total Score, Severity Index, Comorbidity Index), CCI, and COMCOLD were calculated at baseline. The primary outcome was time-to-first moderate-to-severe exacerbation. Cox regression analyses and time-dependent receiver operating characteristic curves were used to assess prognostic performance at 12, 24, and 52 weeks. RESULTS: < 0.001), maintaining significance after adjustment for clinical covariates. CIRS indices demonstrated superior discriminative performance compared to CCI and COMCOLD, with CIRS-SI achieving the highest time-dependent AUC values across all timepoints (0.704, 0.679, and 0.778 at 12, 24, and 52 weeks, respectively). CONCLUSION: CIRS provides superior prognostic accuracy compared to established comorbidity indices in identifying COPD patients at increased risk of exacerbations. These findings highlight the clinical relevance of incorporating a comprehensive, severity-weighted comorbidity assessment in COPD management, supporting the concept of COPD as a complex, multisystem disorder requiring an integrated approach to care.
No takes yet. Share an insight, caveat, or question.
Pirera et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: